Recently diagnosed with HIV? Click here

ATAHC: Australian trial in acute hepatitis C

Clinical trial • Reported • 29 April 2008
This trial is concluded. This means the trial has been completed. The results of the trial are summarised in the 'results' section of this page. You cannot enrol in this trial.

About this trial

This study is following a large group of people with acute hepatitis C virusA small infective organism which is incapable of reproducing outside a host cell. (HCVHepatitis C virus.) to examine why some people naturally clear the virus and some don't. It will also monitor how many people become re-infected after clearing HCV and look into why this happened.

Three months into the study, everyone taking part has the option to undergo a six month course of pegylated interferon alfa 2a (plus ribavirinAn antiviral drug which is effective against a range of viruses including herpes, the hepatitis C virus and several strains of influenza. for those coinfected with HIV) as treatment for their hepatitis C. The purpose of this part of the study is to examine whether treatment is effective in clearing HCV.

Background information

The Trial is in the final stage of study analysis and study papers publication. The investigators anticipate that all trial activities will complete by June 2010.

Official title:Australian Trial in Acute Hepatitis C
What is this trial studying?Existing drug – ribavirin, interferon
Start date:July 2004

This may be the proposed or expected start date for trials which have not yet started.

How many participants will this trial enrol?167

The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.

How long is this trial planned to go for?Participants in this trial will be asked to take the trial drugs for 6 months. Following the conclusion of the trial, participants will be followed up for a further 60 months.
Links to further information:
Can I access this treatment other than by enrolling in this trial?

Pegylated interferon alpha 2a and ribavirinAn antiviral drug which is effective against a range of viruses including herpes, the hepatitis C virus and several strains of influenza. are PBS[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. approved drugs.

Tags:hepatitis C, liver disorders

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

  • At least 16 years old
  • HIV-positive
  • Positive antibody test for hepatitis C virus (HCV)

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

Results:

For a review of outcomes of this trial see attachment: Dore_Gastroenterology_2010

AttachmentSizeType
Dore_Gastroenterology_2010.pdf1.52 MBDore_Gastroenterology_2010.pdfPDF

Disclaimer

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

  • Before making the decision to participate in any clinical research, read our background information.
  • Email NAPWA if you have any questions or comments about this trial
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Clinical trial was first published on 29 April 2008 — more than three years ago.

While the content of this clinical trial was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

Website links

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more